The global market for Inactivated Influenza Vaccine was estimated to be worth US$ 6990 million in 2023 and is forecast to a readjusted size of US$ 10610 million by 2030 with a CAGR of 5.3% during the forecast period 2024-2030

Inactivated Influenza Vaccine - Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Inactivated Influenza Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Inactivated Influenza Vaccine by region & country, by Type, and by Application.

The Inactivated Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Influenza Vaccine.

Market Segmentation

Scope of Inactivated Influenza Vaccine - Market Report

Report Metric	Details
Report Name	Inactivated Influenza Vaccine - Market
Forecasted market size in 2030	US$ 10610 million
CAGR	5.3%
Forecasted years	2024 - 2030
Segment by Type:	Trivalent Influenza Vaccine Quadrivalent Influenza Vaccine
Segment by Application	Children Adolescence Adults Elderly
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	CSL Limited, GSK, Sanofi Pasteur, Viatris, Hualan Biological, AstraZeneca, Sinovac Biotech, Aleph Biomedical, Abbott Laboratories, Novartis International, Changchun Institute of Biological, BCHT, Jiangsu GDK, KM Biologics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Inactivated Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Inactivated Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Inactivated Influenza Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Inactivated Influenza Vaccine - Market size in 2030?

Ans: The Inactivated Influenza Vaccine - Market size in 2030 will be US$ 10610 million.

Who are the main players in the Inactivated Influenza Vaccine - Market report?

Ans: The main players in the Inactivated Influenza Vaccine - Market are CSL Limited, GSK, Sanofi Pasteur, Viatris, Hualan Biological, AstraZeneca, Sinovac Biotech, Aleph Biomedical, Abbott Laboratories, Novartis International, Changchun Institute of Biological, BCHT, Jiangsu GDK, KM Biologics

What are the Application segmentation covered in the Inactivated Influenza Vaccine - Market report?

Ans: The Applications covered in the Inactivated Influenza Vaccine - Market report are Children, Adolescence, Adults, Elderly

What are the Type segmentation covered in the Inactivated Influenza Vaccine - Market report?

Ans: The Types covered in the Inactivated Influenza Vaccine - Market report are Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine

1 Market Overview

1.1 Inactivated Influenza Vaccine Product Introduction

1.2 Global Inactivated Influenza Vaccine Market Size Forecast

1.2.1 Global Inactivated Influenza Vaccine Sales Value (2019-2030)

1.2.2 Global Inactivated Influenza Vaccine Sales Volume (2019-2030)

1.2.3 Global Inactivated Influenza Vaccine Sales Price (2019-2030)

1.3 Inactivated Influenza Vaccine Market Trends & Drivers

1.3.1 Inactivated Influenza Vaccine Industry Trends

1.3.2 Inactivated Influenza Vaccine Market Drivers & Opportunity

1.3.3 Inactivated Influenza Vaccine Market Challenges

1.3.4 Inactivated Influenza Vaccine Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Inactivated Influenza Vaccine Players Revenue Ranking (2023)

2.2 Global Inactivated Influenza Vaccine Revenue by Company (2019-2024)

2.3 Global Inactivated Influenza Vaccine Players Sales Volume Ranking (2023)

2.4 Global Inactivated Influenza Vaccine Sales Volume by Company Players (2019-2024)

2.5 Global Inactivated Influenza Vaccine Average Price by Company (2019-2024)

2.6 Key Manufacturers Inactivated Influenza Vaccine Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Inactivated Influenza Vaccine Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Inactivated Influenza Vaccine

2.9 Inactivated Influenza Vaccine Market Competitive Analysis

2.9.1 Inactivated Influenza Vaccine Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Inactivated Influenza Vaccine Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Vaccine as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Trivalent Influenza Vaccine

3.1.2 Quadrivalent Influenza Vaccine

3.2 Global Inactivated Influenza Vaccine Sales Value by Type

3.2.1 Global Inactivated Influenza Vaccine Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Inactivated Influenza Vaccine Sales Value, by Type (2019-2030)

3.2.3 Global Inactivated Influenza Vaccine Sales Value, by Type (%) (2019-2030)

3.3 Global Inactivated Influenza Vaccine Sales Volume by Type

3.3.1 Global Inactivated Influenza Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Inactivated Influenza Vaccine Sales Volume, by Type (2019-2030)

3.3.3 Global Inactivated Influenza Vaccine Sales Volume, by Type (%) (2019-2030)

3.4 Global Inactivated Influenza Vaccine Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Children

4.1.2 Adolescence

4.1.3 Adults

4.1.4 Elderly

4.2 Global Inactivated Influenza Vaccine Sales Value by Application

4.2.1 Global Inactivated Influenza Vaccine Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Inactivated Influenza Vaccine Sales Value, by Application (2019-2030)

4.2.3 Global Inactivated Influenza Vaccine Sales Value, by Application (%) (2019-2030)

4.3 Global Inactivated Influenza Vaccine Sales Volume by Application

4.3.1 Global Inactivated Influenza Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Inactivated Influenza Vaccine Sales Volume, by Application (2019-2030)

4.3.3 Global Inactivated Influenza Vaccine Sales Volume, by Application (%) (2019-2030)

4.4 Global Inactivated Influenza Vaccine Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Inactivated Influenza Vaccine Sales Value by Region

5.1.1 Global Inactivated Influenza Vaccine Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Inactivated Influenza Vaccine Sales Value by Region (2019-2024)

5.1.3 Global Inactivated Influenza Vaccine Sales Value by Region (2025-2030)

5.1.4 Global Inactivated Influenza Vaccine Sales Value by Region (%), (2019-2030)

5.2 Global Inactivated Influenza Vaccine Sales Volume by Region

5.2.1 Global Inactivated Influenza Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Inactivated Influenza Vaccine Sales Volume by Region (2019-2024)

5.2.3 Global Inactivated Influenza Vaccine Sales Volume by Region (2025-2030)

5.2.4 Global Inactivated Influenza Vaccine Sales Volume by Region (%), (2019-2030)

5.3 Global Inactivated Influenza Vaccine Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Inactivated Influenza Vaccine Sales Value, 2019-2030

5.4.2 North America Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Inactivated Influenza Vaccine Sales Value, 2019-2030

5.5.2 Europe Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Inactivated Influenza Vaccine Sales Value, 2019-2030

5.6.2 Asia Pacific Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Inactivated Influenza Vaccine Sales Value, 2019-2030

5.7.2 South America Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Inactivated Influenza Vaccine Sales Value, 2019-2030

5.8.2 Middle East & Africa Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Inactivated Influenza Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Inactivated Influenza Vaccine Sales Value

6.2.1 Key Countries/Regions Inactivated Influenza Vaccine Sales Value, 2019-2030

6.2.2 Key Countries/Regions Inactivated Influenza Vaccine Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Inactivated Influenza Vaccine Sales Value, 2019-2030

6.3.2 United States Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Inactivated Influenza Vaccine Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Inactivated Influenza Vaccine Sales Value, 2019-2030

6.4.2 Europe Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Inactivated Influenza Vaccine Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Inactivated Influenza Vaccine Sales Value, 2019-2030

6.5.2 China Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

6.5.3 China Inactivated Influenza Vaccine Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Inactivated Influenza Vaccine Sales Value, 2019-2030

6.6.2 Japan Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Inactivated Influenza Vaccine Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Inactivated Influenza Vaccine Sales Value, 2019-2030

6.7.2 South Korea Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Inactivated Influenza Vaccine Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Inactivated Influenza Vaccine Sales Value, 2019-2030

6.8.2 Southeast Asia Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Inactivated Influenza Vaccine Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Inactivated Influenza Vaccine Sales Value, 2019-2030

6.9.2 India Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

6.9.3 India Inactivated Influenza Vaccine Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 CSL Limited

7.1.1 CSL Limited Company Information

7.1.2 CSL Limited Introduction and Business Overview

7.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.1.4 CSL Limited Inactivated Influenza Vaccine Product Offerings

7.1.5 CSL Limited Recent Development

7.2 GSK

7.2.1 GSK Company Information

7.2.2 GSK Introduction and Business Overview

7.2.3 GSK Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.2.4 GSK Inactivated Influenza Vaccine Product Offerings

7.2.5 GSK Recent Development

7.3 Sanofi Pasteur

7.3.1 Sanofi Pasteur Company Information

7.3.2 Sanofi Pasteur Introduction and Business Overview

7.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Sanofi Pasteur Inactivated Influenza Vaccine Product Offerings

7.3.5 Sanofi Pasteur Recent Development

7.4 Viatris

7.4.1 Viatris Company Information

7.4.2 Viatris Introduction and Business Overview

7.4.3 Viatris Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Viatris Inactivated Influenza Vaccine Product Offerings

7.4.5 Viatris Recent Development

7.5 Hualan Biological

7.5.1 Hualan Biological Company Information

7.5.2 Hualan Biological Introduction and Business Overview

7.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Hualan Biological Inactivated Influenza Vaccine Product Offerings

7.5.5 Hualan Biological Recent Development

7.6 AstraZeneca

7.6.1 AstraZeneca Company Information

7.6.2 AstraZeneca Introduction and Business Overview

7.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.6.4 AstraZeneca Inactivated Influenza Vaccine Product Offerings

7.6.5 AstraZeneca Recent Development

7.7 Sinovac Biotech

7.7.1 Sinovac Biotech Company Information

7.7.2 Sinovac Biotech Introduction and Business Overview

7.7.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Sinovac Biotech Inactivated Influenza Vaccine Product Offerings

7.7.5 Sinovac Biotech Recent Development

7.8 Aleph Biomedical

7.8.1 Aleph Biomedical Company Information

7.8.2 Aleph Biomedical Introduction and Business Overview

7.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Aleph Biomedical Inactivated Influenza Vaccine Product Offerings

7.8.5 Aleph Biomedical Recent Development

7.9 Abbott Laboratories

7.9.1 Abbott Laboratories Company Information

7.9.2 Abbott Laboratories Introduction and Business Overview

7.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Abbott Laboratories Inactivated Influenza Vaccine Product Offerings

7.9.5 Abbott Laboratories Recent Development

7.10 Novartis International

7.10.1 Novartis International Company Information

7.10.2 Novartis International Introduction and Business Overview

7.10.3 Novartis International Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Novartis International Inactivated Influenza Vaccine Product Offerings

7.10.5 Novartis International Recent Development

7.11 Changchun Institute of Biological

7.11.1 Changchun Institute of Biological Company Information

7.11.2 Changchun Institute of Biological Introduction and Business Overview

7.11.3 Changchun Institute of Biological Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.11.4 Changchun Institute of Biological Inactivated Influenza Vaccine Product Offerings

7.11.5 Changchun Institute of Biological Recent Development

7.12 BCHT

7.12.1 BCHT Company Information

7.12.2 BCHT Introduction and Business Overview

7.12.3 BCHT Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.12.4 BCHT Inactivated Influenza Vaccine Product Offerings

7.12.5 BCHT Recent Development

7.13 Jiangsu GDK

7.13.1 Jiangsu GDK Company Information

7.13.2 Jiangsu GDK Introduction and Business Overview

7.13.3 Jiangsu GDK Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.13.4 Jiangsu GDK Inactivated Influenza Vaccine Product Offerings

7.13.5 Jiangsu GDK Recent Development

7.14 KM Biologics

7.14.1 KM Biologics Company Information

7.14.2 KM Biologics Introduction and Business Overview

7.14.3 KM Biologics Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.14.4 KM Biologics Inactivated Influenza Vaccine Product Offerings

7.14.5 KM Biologics Recent Development

8 Industry Chain Analysis

8.1 Inactivated Influenza Vaccine Industrial Chain

8.2 Inactivated Influenza Vaccine Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Inactivated Influenza Vaccine Sales Model

8.5.2 Sales Channel

8.5.3 Inactivated Influenza Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Novartis International

Changchun Institute of Biological

BCHT

Jiangsu GDK

KM Biologics

List of Tables

Table 1. Inactivated Influenza Vaccine Market Trends

Table 2. Inactivated Influenza Vaccine Market Drivers & Opportunity

Table 3. Inactivated Influenza Vaccine Market Challenges

Table 4. Inactivated Influenza Vaccine Market Restraints

Table 5. Global Inactivated Influenza Vaccine Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Inactivated Influenza Vaccine Revenue Market Share by Company (2019-2024)

Table 7. Global Inactivated Influenza Vaccine Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Inactivated Influenza Vaccine Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Inactivated Influenza Vaccine Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Inactivated Influenza Vaccine Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Inactivated Influenza Vaccine Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Inactivated Influenza Vaccine

Table 13. Global Inactivated Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Vaccine as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Inactivated Influenza Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Inactivated Influenza Vaccine Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Inactivated Influenza Vaccine Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Inactivated Influenza Vaccine Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Inactivated Influenza Vaccine Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Inactivated Influenza Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Inactivated Influenza Vaccine Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Inactivated Influenza Vaccine Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Inactivated Influenza Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Inactivated Influenza Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Inactivated Influenza Vaccine Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Inactivated Influenza Vaccine Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Inactivated Influenza Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Inactivated Influenza Vaccine Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Inactivated Influenza Vaccine Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Inactivated Influenza Vaccine Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Inactivated Influenza Vaccine Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Inactivated Influenza Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Inactivated Influenza Vaccine Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Inactivated Influenza Vaccine Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Inactivated Influenza Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Inactivated Influenza Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Inactivated Influenza Vaccine Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Inactivated Influenza Vaccine Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Inactivated Influenza Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Inactivated Influenza Vaccine Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Inactivated Influenza Vaccine Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Inactivated Influenza Vaccine Sales Value by Region (2019-2024) & (%)

Table 44. Global Inactivated Influenza Vaccine Sales Value by Region (2025-2030) & (%)

Table 45. Global Inactivated Influenza Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Inactivated Influenza Vaccine Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Inactivated Influenza Vaccine Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Inactivated Influenza Vaccine Sales Volume by Region (2019-2024) & (%)

Table 49. Global Inactivated Influenza Vaccine Sales Volume by Region (2025-2030) & (%)

Table 50. Global Inactivated Influenza Vaccine Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Inactivated Influenza Vaccine Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Inactivated Influenza Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Inactivated Influenza Vaccine Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Inactivated Influenza Vaccine Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Inactivated Influenza Vaccine Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Inactivated Influenza Vaccine Sales Volume, (2025-2030) & (K Units)

Table 57. CSL Limited Company Information

Table 58. CSL Limited Introduction and Business Overview

Table 59. CSL Limited Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. CSL Limited Inactivated Influenza Vaccine Product Offerings

Table 61. CSL Limited Recent Development

Table 62. GSK Company Information

Table 63. GSK Introduction and Business Overview

Table 64. GSK Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. GSK Inactivated Influenza Vaccine Product Offerings

Table 66. GSK Recent Development

Table 67. Sanofi Pasteur Company Information

Table 68. Sanofi Pasteur Introduction and Business Overview

Table 69. Sanofi Pasteur Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Sanofi Pasteur Inactivated Influenza Vaccine Product Offerings

Table 71. Sanofi Pasteur Recent Development

Table 72. Viatris Company Information

Table 73. Viatris Introduction and Business Overview

Table 74. Viatris Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Viatris Inactivated Influenza Vaccine Product Offerings

Table 76. Viatris Recent Development

Table 77. Hualan Biological Company Information

Table 78. Hualan Biological Introduction and Business Overview

Table 79. Hualan Biological Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Hualan Biological Inactivated Influenza Vaccine Product Offerings

Table 81. Hualan Biological Recent Development

Table 82. AstraZeneca Company Information

Table 83. AstraZeneca Introduction and Business Overview

Table 84. AstraZeneca Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. AstraZeneca Inactivated Influenza Vaccine Product Offerings

Table 86. AstraZeneca Recent Development

Table 87. Sinovac Biotech Company Information

Table 88. Sinovac Biotech Introduction and Business Overview

Table 89. Sinovac Biotech Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Sinovac Biotech Inactivated Influenza Vaccine Product Offerings

Table 91. Sinovac Biotech Recent Development

Table 92. Aleph Biomedical Company Information

Table 93. Aleph Biomedical Introduction and Business Overview

Table 94. Aleph Biomedical Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Aleph Biomedical Inactivated Influenza Vaccine Product Offerings

Table 96. Aleph Biomedical Recent Development

Table 97. Abbott Laboratories Company Information

Table 98. Abbott Laboratories Introduction and Business Overview

Table 99. Abbott Laboratories Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Abbott Laboratories Inactivated Influenza Vaccine Product Offerings

Table 101. Abbott Laboratories Recent Development

Table 102. Novartis International Company Information

Table 103. Novartis International Introduction and Business Overview

Table 104. Novartis International Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. Novartis International Inactivated Influenza Vaccine Product Offerings

Table 106. Novartis International Recent Development

Table 107. Changchun Institute of Biological Company Information

Table 108. Changchun Institute of Biological Introduction and Business Overview

Table 109. Changchun Institute of Biological Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. Changchun Institute of Biological Inactivated Influenza Vaccine Product Offerings

Table 111. Changchun Institute of Biological Recent Development

Table 112. BCHT Company Information

Table 113. BCHT Introduction and Business Overview

Table 114. BCHT Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. BCHT Inactivated Influenza Vaccine Product Offerings

Table 116. BCHT Recent Development

Table 117. Jiangsu GDK Company Information

Table 118. Jiangsu GDK Introduction and Business Overview

Table 119. Jiangsu GDK Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 120. Jiangsu GDK Inactivated Influenza Vaccine Product Offerings

Table 121. Jiangsu GDK Recent Development

Table 122. KM Biologics Company Information

Table 123. KM Biologics Introduction and Business Overview

Table 124. KM Biologics Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 125. KM Biologics Inactivated Influenza Vaccine Product Offerings

Table 126. KM Biologics Recent Development

Table 127. Key Raw Materials Lists

Table 128. Raw Materials Key Suppliers Lists

Table 129. Inactivated Influenza Vaccine Downstream Customers

Table 130. Inactivated Influenza Vaccine Distributors List

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

List of Figures

Figure 1. Inactivated Influenza Vaccine Product Picture

Figure 2. Global Inactivated Influenza Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Inactivated Influenza Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Inactivated Influenza Vaccine Sales Volume (2019-2030) & (K Units)

Figure 5. Global Inactivated Influenza Vaccine Sales Price (2019-2030) & (US$/Unit)

Figure 6. Inactivated Influenza Vaccine Report Years Considered

Figure 7. Global Inactivated Influenza Vaccine Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Inactivated Influenza Vaccine Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Inactivated Influenza Vaccine Revenue in 2023

Figure 10. Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Trivalent Influenza Vaccine Picture

Figure 12. Quadrivalent Influenza Vaccine Picture

Figure 13. Global Inactivated Influenza Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Inactivated Influenza Vaccine Sales Value Market Share by Type, 2023 & 2030

Figure 15. Global Inactivated Influenza Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Inactivated Influenza Vaccine Sales Volume Market Share by Type, 2023 & 2030

Figure 17. Global Inactivated Influenza Vaccine Price by Type (2019-2030) & (US$/Unit)

Figure 18. Product Picture of Children

Figure 19. Product Picture of Adolescence

Figure 20. Product Picture of Adults

Figure 21. Product Picture of Elderly

Figure 22. Global Inactivated Influenza Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 23. Global Inactivated Influenza Vaccine Sales Value Market Share by Application, 2023 & 2030

Figure 24. Global Inactivated Influenza Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 25. Global Inactivated Influenza Vaccine Sales Volume Market Share by Application, 2023 & 2030

Figure 26. Global Inactivated Influenza Vaccine Price by Application (2019-2030) & (US$/Unit)

Figure 27. North America Inactivated Influenza Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 28. North America Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 29. Europe Inactivated Influenza Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 30. Europe Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 31. Asia Pacific Inactivated Influenza Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 32. Asia Pacific Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 33. South America Inactivated Influenza Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 34. South America Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 35. Middle East & Africa Inactivated Influenza Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 36. Middle East & Africa Inactivated Influenza Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 37. Key Countries/Regions Inactivated Influenza Vaccine Sales Value (%), (2019-2030)

Figure 38. Key Countries/Regions Inactivated Influenza Vaccine Sales Volume (%), (2019-2030)

Figure 39. United States Inactivated Influenza Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 40. United States Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 41. United States Inactivated Influenza Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 42. Europe Inactivated Influenza Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 43. Europe Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 44. Europe Inactivated Influenza Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 45. China Inactivated Influenza Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 46. China Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 47. China Inactivated Influenza Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 48. Japan Inactivated Influenza Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 49. Japan Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 50. Japan Inactivated Influenza Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 51. South Korea Inactivated Influenza Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 52. South Korea Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 53. South Korea Inactivated Influenza Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 54. Southeast Asia Inactivated Influenza Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 55. Southeast Asia Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 56. Southeast Asia Inactivated Influenza Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 57. India Inactivated Influenza Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 58. India Inactivated Influenza Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 59. India Inactivated Influenza Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 60. Inactivated Influenza Vaccine Industrial Chain

Figure 61. Inactivated Influenza Vaccine Manufacturing Cost Structure

Figure 62. Channels of Distribution (Direct Sales, and Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Influenza Vaccine Market

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions